Cigna Corporation (NYSE:CI) has been given an average rating of “Buy” by the eighteen brokerages that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $200.67.

A number of equities analysts recently commented on CI shares. Morgan Stanley raised their target price on Cigna from $195.00 to $223.00 and gave the company an “overweight” rating in a report on Friday, November 3rd. Royal Bank Of Canada restated an “outperform” rating and set a $220.00 target price (up from $185.00) on shares of Cigna in a report on Friday, November 3rd. Citigroup raised their target price on Cigna from $185.00 to $198.00 and gave the company a “buy” rating in a report on Monday, August 7th. Jefferies Group restated a “buy” rating and set a $190.00 target price (down from $199.00) on shares of Cigna in a report on Friday, August 4th. Finally, Zacks Investment Research cut Cigna from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th.

In other news, insider Christopher J. Hocevar sold 8,387 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $200.32, for a total transaction of $1,680,083.84. Following the sale, the insider now owns 12,363 shares of the company’s stock, valued at approximately $2,476,556.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William D. Zollars sold 1,232 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $187.23, for a total value of $230,667.36. The disclosure for this sale can be found here. Insiders sold a total of 36,203 shares of company stock worth $7,211,251 in the last ninety days. 1.30% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of CI. JPMorgan Chase & Co. raised its position in shares of Cigna by 40.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,088,728 shares of the health services provider’s stock worth $684,413,000 after acquiring an additional 1,184,632 shares in the last quarter. Investec Asset Management LTD raised its position in shares of Cigna by 35.4% during the 3rd quarter. Investec Asset Management LTD now owns 1,849,598 shares of the health services provider’s stock worth $345,764,000 after acquiring an additional 483,904 shares in the last quarter. FMR LLC raised its position in shares of Cigna by 6.7% during the 2nd quarter. FMR LLC now owns 6,909,638 shares of the health services provider’s stock worth $1,156,604,000 after acquiring an additional 432,978 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Cigna by 4,082.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 438,231 shares of the health services provider’s stock worth $73,355,000 after acquiring an additional 427,754 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Cigna by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,130,735 shares of the health services provider’s stock worth $2,867,514,000 after acquiring an additional 424,469 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Cigna (NYSE:CI) traded up $5.28 during midday trading on Thursday, hitting $205.83. The stock had a trading volume of 1,530,000 shares, compared to its average volume of 1,352,192. The stock has a market cap of $49,445.54, a PE ratio of 19.32, a PEG ratio of 1.53 and a beta of 0.49. The company has a current ratio of 0.39, a quick ratio of 0.39 and a debt-to-equity ratio of 0.37. Cigna has a fifty-two week low of $131.03 and a fifty-two week high of $207.21.

Cigna (NYSE:CI) last released its quarterly earnings results on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, topping analysts’ consensus estimates of $2.36 by $0.47. The business had revenue of $10.38 billion during the quarter, compared to analysts’ expectations of $10.17 billion. Cigna had a return on equity of 18.85% and a net margin of 5.74%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.94 EPS. analysts expect that Cigna will post 10.34 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Cigna Corporation (CI) Given Consensus Recommendation of “Buy” by Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/30/cigna-corporation-ci-given-consensus-recommendation-of-buy-by-brokerages.html.

About Cigna

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Analyst Recommendations for Cigna (NYSE:CI)

Receive News & Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related companies with MarketBeat.com's FREE daily email newsletter.